FDA Tweaks Guidance on Clinical Pharmacology Data for Demonstrating Biosimilarity

Generic Line
A A
The FDA has made modest changes to its guidance on clinical pharmacology testing for biosimilars.

To View This Article:

Login

Subscribe To Generic Line